Eukaryotic initiation factor 5A (EIF5A) is found in diabetes-susceptibility loci in mouse and human. eIF5A is the only protein known to contain hypusine (hydroxyputrescine lysine), a polyamine-derived amino acid formed post-translationally in a reaction catalyzed by deoxyhypusine synthase (DHPS). Previous studies showed pharmacologic blockade of DHPS in type 1 diabetic NOD mice and type 2 diabetic db/db mice improved glucose tolerance and preserved beta-cell mass, which suggests that hypusinated eIF5A (eIF5A Hyp ) may play a role in diabetes pathogenesis by direct action on the beta cells and/or altering the adaptive or innate immune responses. To translate these findings to human, we examined tissue from individuals with and without type 1 and type 2 diabetes to determine the expression of eIF5A Hyp . We detected eIF5A Hyp in beta cells, exocrine cells and immune cells; however, there was also unexpected enrichment of eIF5A Hyp in pancreatic polypeptide-expressing PP cells. Interestingly, the presence of eIF5A Hyp coexpressing PP cells was not enhanced with disease. These data identify new aspects of eIF5A biology and highlight the need to examine human tissue to understand disease.
INTRODUCTION 1
The mechanisms underlying the pathogeneses of type 1 diabetes (T1D) and type in mouse models of diabetes [10, 11] , and that eIF5A Hyp also appears to be required for 27 the activation and proliferation of effector T helper cells [12] . Moreover, reducing the 28 hypusination of eIF5A in NOD mice, a model of T1D, by pharmacological inhibition of 29 DHPS resulted in reduced insulitis, improved glucose tolerance and preserved beta cell 30 mass [12] . Similarly, pharmacological blockade of DHPS in db/db mice [13] , a model of 31 T2D improved glucose tolerance and enhanced beta cell mass [14] . Together these data 32 suggest that eIF5A Hyp may play a critical role in the pathogenesis of diabetes and 33 altering the expression of eIF5A Hyp may improve diabetes outcomes long-term.
34
To translate these findings to human, a greater understanding of eIF5A Hyp We previously developed and characterized a novel antibody that recognizes the 47 unique amino acid hypusine, formed exclusively through posttranslational modification of 48 the Lys50 residue of eIF5A (eIF5A Hyp ) [10] . In this study, we utilized this antibody to 49 investigate the expression of eIF5A Hyp in mouse and human pancreas tissue and 50 isolated islets as well as human spleen tissue, to characterize the expression pattern of disease. To that end, we first confirmed the presence of eIF5A Hyp in islets isolated from 53 mouse and human pancreas as well as in mouse pancreas and human acinar (exocrine) 54 tissue ( Fig 1A) .
55
We next utilized the RIP-cre;R26R Tomato mouse model wherein the insulin-56 expressing cells were labeled with a lineage trace, thereby generating beta cells indelibly 57 marked with fluorescent reporter (tomato) expression. Islet cells from RIP-cre;R26R Tomato 58 and control animals were sorted by FACS, using the presence and absence of tomato 59 expression to separate cells into two populations: beta cells (tomato-positive) and non-60 beta cells (tomato-negative). The cell types represented in the "non-beta cell" sample 61 would include (ordered from largest population to smallest): glucagon-expressing alpha 62 cells, somatostatin-expressing delta cells, pancreatic polypeptide-expressing PP cells, 63 ghrelin-expressing epsilon cells, exocrine cells (a possible contaminant from the process 64 of islet isolation) and support cells including endothelial cells. A similar quantity of 65 tomato-positive beta cells (1.92x10 5 cells) and tomato-negative non-beta cells (2.13x10 5 66 cells) were collected ( Fig EV1) . Subsequent western blot analysis identified that eIF5A Hyp 67 was present in nearly identical abundance in both the beta cell (tomato-positive) and 68 non-beta cell (tomato-negative) populations ( Fig 1B) . The expression of Pdx1 confirms 69 the enrichment of beta cells in the tomato positive cells; the lower level of Pdx1 70 expression in the non-beta cell fraction can be attributed to the somatostatin-expressing 71 delta cells. These data demonstrate that eIF5A Hyp is expressed in both the beta cell and 72 non-beta cell fractions; however, the specific non-beta cell type(s) expressing eIF5A Hyp 73 cannot be clarified from these data. Therefore, to characterize the spatial distribution of 74 eIF5A Hyp expression pattern in the islet, we performed co-immunofluorescence staining 75 for eIF5A Hyp and islet hormones in mouse pancreas tissue. Whereas relatively weak 76 immunostaining of eIF5A Hyp was found throughout the pancreas and islets, robust pancreatic polypeptide ( Fig 1C, D) . Based on the known abundance of islet cell 79 populations [15-17], PP cells would represent only a small proportion of the "tomato-80 negative non-beta cell" FACS sample, yet the abundance of eIF5A Hyp expression is 81 nearly equivalent to that observed in the pure "tomato-positive beta cell" FACS sample 82 ( Fig 1B) . Thus, the robust expression of eIF5A Hyp in the PP cells is consistent with the 83 immunoblot data. 
88
(nPOD). A cohort of tissues from donors with and without T2D were provided ( Table 1 ).
89
Both pancreas and spleen tissues were acquired from each donor; age, gender, ethnicity 90 and BMI were matched where possible. Given the relatively small size of the cohort, 91 quantitative evaluations were not possible. Therefore, we evaluated the presence or 92 absence of eIF5A Hyp , its cell-type expression pattern, and its expression correlation with 93 disease.
94
Pancreas tissue sections were co-immunostained with the eIF5A Hyp -specific 95 antibody and antibodies that recognized the hormones expressed by each of the 96 endocrine cell populations in the islet (insulin, glucagon, somatostatin, ghrelin and 97 pancreatic polypeptide). Co-localization was not observed between eIF5A Hyp and insulin 98 (Fig 2A,B) , glucagon ( Fig 2C,D) , ghrelin (Fig 2E,F) , or somatostatin ( Fig 2G,H ).
99
However, as observed in the mouse pancreas, cells expressing pancreatic polypeptide 100 were identified to co-express high levels of eIF5A Hyp in control pancreas tissue ( Fig 3A) .
101
These cells also expressed chromograninA, which confirms their identity as 102 neuroendocrine cells ( Fig 3B) . The co-localization of eIF5A Hyp with pancreatic pattern reveals localization in different compartments, with the eIF5A Hyp pattern 107 suggestive of localization in the endoplasmic reticulum ( Fig 3E) . 
159
Clearly, a greater understanding is required for the role of PP cells in the pathogenesis 160 of diabetes.
161
Given that much of the published and ongoing work on hypusine biosynthesis in 162 mice has studied eIF5A Hyp in the context of diabetes, we had hypothesized that eIF5A Hyp 163 expression would be identified predominantly in the insulin-producing beta cell 164 population. Our western blot analysis did reveal eIF5A Hyp expression in human islets. 
416
In controls (matched for age, gender and BMI) and T2D pancreas, we evaluated the co- 
